

Bibliografia PNCT

IFP, 19/12/2019

1. Core Curriculum on Tuberculosis: What the Clinician Should Know. Sixth Edition, 2013. CDC. https://www.cdc.gov/tb/education/corecurr/pdf/corecurr_all.pdf
2. Crudu V. Controlul infecției în instituțiile medicale implicate în managementul tuberculozei rezistente. Ghid. Chișinău, 2012.
3. Dlodlo RA, Brigden G, Haldal E, Allwood B, Chiang C-Y, Fujiwara PI, Graham SM, Guillerm N, Harries AD, Koura KG, Kumar AMV, Lin Y, Meghji J, Mortimer K, Piubello A, Roth B, Satyanarayana S, Sekadde M, Solovič I, Tonsing J, Van Deun A. Management of Tuberculosis: a Guide to Essential Practice. Paris, France: International Union Against Tuberculosis and Lung Disease, 2019.
4. EMCB. Educație medicală continuă. Modul PNEUMOLOGIE [1 mai 2013 – 30 aprilie 2014] Creditat prin decizia CMR nr. 6653/ 21.12.2012
5. ICD-11 International Classification of Diseases 11th Revision. The global standard for diagnostic health information. <https://icd.who.int/en>.
6. Guidelines for Clinical and Operational Management of Drug-Resistant Tuberculosis. Editor: José A. Caminero. International Union Against Tuberculosis and Lung Disease, 2013. https://www.theunion.org/what-we-do/publications/technical/english/mdr-tbguide_6-19-13_web.pdf
7. Programul National de Control al Tuberculozei (PNCT) pentru anii 2016 –2020, aprobat prin Hotărârea Guvernului RM nr. 1160, din 20.10.2016. <http://lex.justice.md/md/367268/>
8. Protocolul clinic național “Tuberculoza la copil”. Chișinău, 2017. http://ftiziopneumologie.asm.md/files/u1/PC_TB_copil_20-09-2017.pdf
9. Schaefer Christof, Peters Paul W.J., Miller Richard K. Drugs During Pregnancy and Lactation. 3rd Edition. Academic Press. 2014
10. The PIH Guide to the Medical Management of Multidrug-Resistant Tuberculosis. 2nd edition. Partners in health, 2013. https://parthealth.3cdn.net/b0233c0e1e4088e07b_unm6vyf2f.pdf
11. TB CARE I. International Standards for Tuberculosis Care, Edition 3. TB CARE I, The Hague, 2014. https://www.who.int/tb/publications/ISTC_3rdEd.pdf
12. Tuberculosis: Practical guide for clinicians, nurses, laboratory technicians and medical auxiliaries. Medecins Sans Frontieres / MSF. Partners in Health, 2014 edition. http://refbooks.msf.org/msf_docs/en/tuberculosis/tuberculosis_en.pdf
13. WHO consolidated guidelines on drug-resistant tuberculosis treatment. WHO, 2019. <https://www.who.int/tb/publications/2019/consolidated-guidelines-drug-resistant-TB-treatment/en/>
14. WHO policy on collaborative TB/HIV activities: guidelines for national programmes and other stakeholders. WHO, 2012. https://www.who.int/tb/publications/2012/tb_hiv_policy_9789241503006/en/
15. WHO. Chest radiography in tuberculosis detection. Summary of current WHO recommendations and guidance on programmatic approaches. WHO, 2016. <https://www.who.int/tb/publications/chest-radiography/en/>
16. WHO. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. WHO, 2014. https://www.who.int/tb/publications/pmdt_companionhandbook/en/
17. WHO. Definitions and reporting framework for tuberculosis 2013 revision, updated December 2014. WHO, 2014. <https://www.who.int/tb/publications/definitions/en/>
18. WHO. Global tuberculosis report 2019. WHO, 2019. <https://www.who.int/tb/publications/en/>
19. WHO. Guideline: Nutritional care and support for patients with tuberculosis. WHO, 2013. https://apps.who.int/iris/bitstream/handle/10665/94836/9789241506410_eng.pdf?sequence=1
20. WHO. Guidelines for intensified case-finding and isoniazid preventive therapy for people living with HIV in resource constrained settings. Geneva, Department of HIV/AIDS, Stop TB Department, 2011. https://apps.who.int/iris/bitstream/handle/10665/44472/9789241500708_eng.pdf?sequence=1
21. WHO. Latent tuberculosis infection. Updated and consolidated guidelines for programmatic management. WHO, 2018. <https://www.who.int/tb/publications/2018/latent-tuberculosis-infection/en/>

22. WHO. Management of tuberculosis and HIV coinfection. Clinical Protocol for the WHO European Region (2013 revision). WHO, 2013. http://www.euro.who.int/_data/assets/pdf_file/0004/78124/E90840_Chapter_4.pdf
23. WHO. Recommendation on 36 months isoniazid preventive therapy to adults and adolescents living with HIV in resource-constrained and high TB and HIV-prevalence settings: 2015 update. WHO, 2015. https://www.who.int/tb/challenges/hiv/2015_ipt_update/en/
24. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach - Second edition. WHO, 2016. <https://www.who.int/hiv/pub/arv/arv-2016/en/>
25. WHO. Recommendations for investigating contacts of persons with infectious tuberculosis in low- and middle-income countries. WHO, 2012. https://apps.who.int/iris/bitstream/handle/10665/77741/9789241504492_eng.pdf?sequence=1&isAllowed=y
26. WHO. Systematic screening for active tuberculosis: an operational guide. WHO, 2015. https://www.who.int/tb/publications/systematic_screening/en/
27. WHO. Systematic screening for active tuberculosis: principles and recommendations. WHO, 2013. <https://www.who.int/tb/tbscreening/en/>
28. WHO. The role of surgery in the treatment of pulmonary TB and multidrug- and extensively drug-resistant TB. WHO Regional Office for Europe, 2014. <http://www.euro.who.int/en/health-topics/communicable-diseases/tuberculosis/publications/2014/the-role-of-surgery-in-the-treatment-of-pulmonary-tb-and-multidrug-and-extensively-drug-resistant-tb>
29. WHO. The use of bedaquiline* in the treatment of multidrug-resistant tuberculosis. Interim policy guidance. WHO, 2013. <https://www.who.int/tb/publications/mdrtb-treatment-guideline/en/>
30. WHO. The use of delamanid in the treatment of multidrug-resistant tuberculosis in children and adolescents: Interim policy guidance. WHO, 2016. https://www.who.int/tb/publications/Delamanid_interim_policy/en/
31. WHO position statement on the use of delamanid for multidrug-resistant tuberculosis. WHO, 2018. https://www.who.int/tb/publications/2018/Position_Paper_Delamanid/en/
32. WHO. Guidelines for treatment of drug-susceptible tuberculosis and patient care (2017 update). https://www.who.int/tb/publications/2017/dstb_guidance_2017/en/
33. WHO. Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children. WHO Policy update, 2014. https://www.who.int/tb/publications/xpert_policyupdate/en/
34. WHO. The use of molecular line probe assays for the detection of resistance to second-line anti-tuberculosis drugs. Policy guidance. WHO, 2016. <https://www.who.int/tb/publications/policy-guidance-molecular-line/en/>
35. WHO. Guidelines on tuberculosis infection prevention and control, 2019 update. <https://www.who.int/tb/publications/2019/guidelines-tuberculosis-infection-prevention-2019/en/>
36. WHO. Handbook for the use of digital technologies to support tuberculosis medication adherence. WHO, 2018. https://www.who.int/tb/publications/2018/TB_medication_adherence_handbook_2018/en/
37. WHO. Compendium of WHO guidelines and associated standards: ensuring optimum delivery of the cascade of care for patients with tuberculosis. Second Edition - June 2018. https://www.who.int/tb/publications/Compendium_WHO_guidelines_TB_2017/en/
38. WHO. The immunological basis for immunization series: module 5: tuberculosis. WHO, 2011. <https://www.medbox.org/the-immunological-basis-for-immunization-series-module-5-tuberculosis/preview>
39. WHO. Algorithm for laboratory diagnosis and treatment-monitoring of pulmonary tuberculosis and drug-resistant tuberculosis using state-of-the-art rapid molecular diagnostic technologies. WHO, 2017. http://www.euro.who.int/_data/assets/pdf_file/0006/333960/ELI-Algorithm.pdf
40. WHO. Rapid Communication: Key changes to the treatment of drug-resistant tuberculosis. WHO, December, 2019. https://www.who.int/tb/publications/2019/rapid_communications_MDR/en/?fbclid=IwAR1Y0etu800wFX-016gVpsDXNJC1PLn8o-5IfN6PGWaoX1TM5_gr-YbCJS0